Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1642
This examiner grants 67% of resolved cases
Yan Xiao is an examiner in Art Unit 1642 of Tech Center 1600. He has 770 resolved cases and an allowance rate of 67.3%. The median days to allowance is 1071, which is a standard duration for biological and chemical examinations. These figures indicate a balanced prosecution environment with a good probability of success. Practitioners should find the 67.3% allowance rate to be a favorable starting point for their applications.
The interview lift is 52.7%, which is exceptionally high. This suggests that interviews are an extremely effective way to secure an allowance with this examiner, nearly doubling the baseline probability. Practitioners should almost always consider an interview as a central part of their strategy. The 770 resolved cases provide a very strong statistical foundation for these metrics. With a 67.3% allowance rate and a 52.7% lift, the data strongly supports active engagement through oral advocacy. The 1071 days to allowance provides a clear benchmark for planning the prosecution timeline.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18286471 | ANTI-C1s ANTIBODY | Non-Final OA | Chugai Seiyaku Kabushiki Kaisha |
| 18267835 | POLYPEPTIDE | Non-Final OA | UCL Business Ltd |
| 18263217 | MULTABODY CONSTRUCTS, COMPOSITIONS, AND METHODS | Non-Final OA | THE HOSPITAL FOR SICK CHILDREN |
| 18025883 | A Scoring Method for an Anti-B7H4 Antibody-Drug Conjugate Therapy | Final Rejection | Medimmune Limited |
| 18316672 | EPHA3 AND MULTI-VALENT TARGETING OF TUMORS | Final Rejection | Wake Forest University Health Sciences |
| 17926206 | METHODS OF TREATING HER2 POSITIVE CANCER WITH TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND AN OXALIPLATIN-BASED CHEMOTHERAPY | Final Rejection | Seagen Inc. |
| 18261765 | TUMOR-INFILTRATING LYMPHOCYTES WITH MEMBRANE BOUND INTERLEUKIN 15 AND USES THEREOF | Non-Final OA | OBSIDIAN THERAPEUTICS, INC. |
| 18282667 | METHODS FOR THE DIAGNOSIS AND TREATMENT OF T CELL-LYMPHOMAS | Final Rejection | UNIVERSITÉ PARIS-EST CRÉTEIL VAL DE MARNE |
| 18025684 | ANTIBODY CONSTRUCTS TO TARGET T CELL RESPONSES TO SARS-COV PROTEIN EXPRESSING CELLS, THEIR DESIGN AND USES | Non-Final OA | Greffex, Inc. |
| 18267914 | Tetravalent FZD and WNT Co-Receptor Binding Antibody Molecules and Uses Thereof | Non-Final OA | AntlerA Therapeutics Inc. |
| 18016316 | CANCER ANTIGEN FOR EARLY CANCER DETECTION | Non-Final OA | UCT RESEARCH AND DEVELOPMENT INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy